Eli Lilly says about 100 jobs will be lost in its dry products operations as it rejiggers tablet and capsule production over the next several years, but that employees will have the chance to move to other positions, like in its growing insulin operations.
Immunocore has struck another cancer R&D pact with one of the world's top drugmakers, signing a deal with Eli Lilly that'll both bring in short-term revenue and help the biotech build value in its proprietary pipeline.
Scientists at drug giant Eli Lilly have found that a combination therapy may be more effective at removing clumps of amyloid-β protein--widely thought to contribute to the development of Alzheimer's disease--than the use of one therapy in mice.
Animal health, which for decades was little more than a side business for big pharma companies, has emerged as a beacon of growth and an important profit driver in the industry. The rise of animal health as a growth engine has set off a flurry of deal making, attracted an influx of capital and created an increasingly dynamic marketplace for pet and livestock pharmaceuticals.
Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until at least mid-2016. But now, it's filed another, wider suit.
Sanofi has filed another lawsuit against Eli Lilly in hopes of beating back a biosimilar challenge for its top-selling insulin product, claiming its rival's in-development knockoff infringes its intellectual property.
Eli Lilly is partnering with Beijing-based Yabao Pharmaceuticals on the development of its early-stage diabetes drug LY2608204.
It has been a big couple of years for the animal health industry. With FierceAnimalHealth, we will be keeping tabs on a slew of companies that are new to us and so we urge you to help us get to know you and to keep us apprised of the essential news in the industry. And please pass along your suggestions.
Sanofi's Lantus is not only the best-selling diabetes drug in the world; it is one of the best selling drugs in the world with $7.6 billion in 2013 revenues. But the foundation for this juggernaut is starting to crack. The EU Friday recommended approval a biosimilar of Lantus developed by Eli Lilly and Boehringer Ingelheim.
Eli Lilly and Boehringer Ingelheim have convinced European regulators to recommend their biosimilar of Sanofi's Lantus, the world's top-selling insulin, setting the stage for a near-term approval and launch once the reference product comes off patent next year.